Summary of published literature related to single cell analyses in lymphoma
| Disease entity . | Platforms . | Main focus . | Authors . | Reference . |
|---|---|---|---|---|
| DLBCL | scRNA-seq, cell-free DNA | Biomarkers of CAR T-cell therapy | Deng et al | 6 |
| DLBCL | scRNA-seq, bulk RNA-seq | Dissecting cellular heterogeneity | Steen et al | 44 |
| DLBCL, follicular lymphoma | scRNA-seq | Intratumor heterogeneity and personalized therapy | Roider et al | 43 |
| Follicular lymphoma | scRNA-seq | Subclones of cancer cells and Treg | Andor et al | 36 |
| Follicular lymphoma | scRNA-seq | Cancer cells and TFH cells | Haebe et al | 38 |
| Follicular lymphoma | scRNA-seq, MC-IF | Nonhematopoietic cells | Abe et al | 4 |
| Follicular lymphoma | scRNA-seq, MC-IF | Cytotoxic CD4+ cells and cancer cells with low MHC expression | Han et al | 45 |
| GCB cell | scRNA-seq, bulk RNA-seq | Cell of origin (follicular lymphoma) | Milpied et al | 40 |
| GCB cell | scRNA-seq, bulk RNA-seq | Cell of origin (DLBCL) | Holmes et al | 39 |
| Mantle cell lymphoma | scRNA-seq, bulk RNA-seq | Ibrutinib resistance | Zhang et al | 42 |
| DLBCL, CHL | IMC | Spatial classification | Colombo et al | 48 |
| CHL | scRNA-seq, IMC | MHC-II expression on HRS cells and LAG3+ Treg | Aoki et al | 5 |
| CHL | scRNA-seq, MC-IF | CXCL13+ helper T cells | Aoki et al | 41 |
| CHL | CyTOF, TCR | Biomarkers for PD-1 blockade | Cader et al | 79 |
| CHL | CyTOF | T-bet+ T cells | Cader et al | 76 |
| CHL | MC-IF | PDL1+ macrophages | Carey et al | 90 |
| CHL | MC-IF | CTLA4+CD4+ T cells | Patel et al | 91 |
| CHL | scRNA-seq, MC-IF | TOX2+CD4+ T cells | Veldman et al | 80 |
| Disease entity . | Platforms . | Main focus . | Authors . | Reference . |
|---|---|---|---|---|
| DLBCL | scRNA-seq, cell-free DNA | Biomarkers of CAR T-cell therapy | Deng et al | 6 |
| DLBCL | scRNA-seq, bulk RNA-seq | Dissecting cellular heterogeneity | Steen et al | 44 |
| DLBCL, follicular lymphoma | scRNA-seq | Intratumor heterogeneity and personalized therapy | Roider et al | 43 |
| Follicular lymphoma | scRNA-seq | Subclones of cancer cells and Treg | Andor et al | 36 |
| Follicular lymphoma | scRNA-seq | Cancer cells and TFH cells | Haebe et al | 38 |
| Follicular lymphoma | scRNA-seq, MC-IF | Nonhematopoietic cells | Abe et al | 4 |
| Follicular lymphoma | scRNA-seq, MC-IF | Cytotoxic CD4+ cells and cancer cells with low MHC expression | Han et al | 45 |
| GCB cell | scRNA-seq, bulk RNA-seq | Cell of origin (follicular lymphoma) | Milpied et al | 40 |
| GCB cell | scRNA-seq, bulk RNA-seq | Cell of origin (DLBCL) | Holmes et al | 39 |
| Mantle cell lymphoma | scRNA-seq, bulk RNA-seq | Ibrutinib resistance | Zhang et al | 42 |
| DLBCL, CHL | IMC | Spatial classification | Colombo et al | 48 |
| CHL | scRNA-seq, IMC | MHC-II expression on HRS cells and LAG3+ Treg | Aoki et al | 5 |
| CHL | scRNA-seq, MC-IF | CXCL13+ helper T cells | Aoki et al | 41 |
| CHL | CyTOF, TCR | Biomarkers for PD-1 blockade | Cader et al | 79 |
| CHL | CyTOF | T-bet+ T cells | Cader et al | 76 |
| CHL | MC-IF | PDL1+ macrophages | Carey et al | 90 |
| CHL | MC-IF | CTLA4+CD4+ T cells | Patel et al | 91 |
| CHL | scRNA-seq, MC-IF | TOX2+CD4+ T cells | Veldman et al | 80 |
CAR, chimeric antigen receptor; DLBCL, diffuse large B-cell lymphoma.